REFERENCES
- Roberts JG, Gravelle 1H, Baum M, Bligh AS, Leach KG, Hughes LE. Evaluation of radio-graphy and isotopic scintigraphy for detecting skeletal metastases in breast cancer. Lancet 1976; i: 237–9.
- Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70: 295–302.
- O'Donoghue JM, Rogers E, Grimes H, et al. A reappraisal of serial isotope bone scans in prostate cancer. Br J Rad 1993; 66: 672–81.
- Delmas PD. Biochemical markers of bone remo-deling in osteoporosis. In: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD, editors. Osteoporosis 96. International Congress, series 1118. Amsterdam: Elsevier, 1996: 191–204.
- Kostenuit PJ, Sanchez Sweatman 0, Orv FW, Singh G. Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 1996; 14: 19 — 26.
- Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348–51.
- Risteli L. Marcadores oseos procedentes del coldgeno tipo I: PICP, ICTP y PINP. Revista Espanola de Enfermedades Metabolicas Oseas 1996; 5: 81–5.
- Schröder FH, Hermanek P, Denis WR, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The Prostate Supplement 1992; 4: 129–38.
- Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for the intact aminoterminal propeptide of human type I procollagen. Clin Chem 1996; 42: 947–54.
- Panigrahi K, Delmans PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline-phosphatase in serum. Clin Chem 1994; 40: 822–8.
- Withold W, Schulte U, Reinaver H. Method for determination of bone alkaline phosphatase activ-ity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases. Clin Chem 1996; 42: 210–7.
- Dominguez C, Sosa M, De la Piedra C, Traba ML. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteo-porosis Int 1998; 8: 147–51.
- Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994; 152: 1358–68.
- Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57–60.
- Goldberg DM, Ellis G. An assessment of serum acid and alkaline phosphatase determinations in prostatic cancer with a clinical validation of an acid phosphatase assay utilizing adenosine 3'-monophosphate as substrate. J Clin Pathol 1974; 27: 140–4.
- Wajsman Z, Chu T, Bross D, et al. Clinical significance of serum alkaline phosphatase iso-enzyme levels in advanced prostatic carcinoma. J Urol 1978; 119: 244–50.
- Diaz Martin MA, Martin I, Soldevilla MJ, et al. Estudio de la reactividad cruzada en la determina-ción de la isoenzima ósea de la fosfatasa alcalina por dos métodos: Tandem R-Ostase y Alkphase-B, el primero un IRMA y el segundo un ELISA. Revista Espanola de Enfermedades Metabolicas Oseas 1995; 4 (Suppl A): 21.
- Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with meta-bolic bone disease. J Clin Endocrinol Metab 1993; 77: 1046 — 53.
- Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninutto M, Plebani M. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin Chim Acta 1994; 226: 151–8.
- Houzé P, Ranaivosoar R, Prost AC, Lonchampt MF. Metastases osseuses des cancers de la prostate: apport du dosage spécifique de la phosphatase alkaline osseuse. Immunoanal Biol Spec 1995; 10: 27–33.
- Casetta G, Gamba P, Piana P, Pecchio F, Tizzani A. Measurement of skeletal alkaline phosphatase in prostatic carcinoma 1995; Minerva Urol Nefrol 47: 9–12.